<!DOCTYPE html>
<html lang="en" dir="ltr">
    <head>
        <meta charset="utf-8">
        <link rel="stylesheet" href="style.css">
        <title> Omnibuster Section </title>
    </head>

    <body>
        <div class="section">
            <h1> Section s3201 </h1>
            <p> <section id="d3355e14005" identifier="/us/bill/116/hr/748/dA/tIII/stA/ptII/sptA/s3201" style="-uslm-lc:I650144"><num value="3201">SEC. 3201. </num><heading>COVERAGE OF DIAGNOSTIC TESTING FOR COVID–19.</heading><content class="indent0 fontsize10" style="-uslm-lc:I650120">  Paragraph (1) of section 6001(a) of division F of the Families First Coronavirus Response Act (<ref href="/us/pl/116/127">Public Law 116–127</ref>) <amendingAction type="amend">is amended</amendingAction> to read as follows:<quotedContent><paragraph class="indent1 fontsize10" style="-uslm-lc:I650122"><num style="-uslm-lc:emspace2" value="1">“(1) </num><chapeau>An in vitro diagnostic test defined in <a href="https://www.law.cornell.edu/cfr/text/21/809.3"><ref href="/us/cfr/t21/s809.3">section 809.3 of title 21, Code of Federal Regulations</ref></a> (or successor regulations) for the detection of SARS–CoV–2 or the diagnosis of the virus that causes COVID–19, and the administration of such a test, that—</chapeau><subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="A">“(A) </num><content>is approved, cleared, or authorized under section 510(k), 513, 515, or 564 of the Federal Food, Drug, and Cosmetic Act (<a href="https://www.law.cornell.edu/uscode/text/21/360"><ref href="/us/usc/t21/s360/k">21 U.S.C. 360(k)</ref></a>, 360c, 360e, 360bbb–3);</content>
</subparagraph>
<subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="B">“(B) </num><content>the developer has requested, or intends to request, emergency use authorization under section 564 of the Federal Food, Drug, and Cosmetic Act (<a href="https://www.law.cornell.edu/uscode/text/21/360bbb–3"><ref href="/us/usc/t21/s360bbb–3">21 U.S.C. 360bbb–3</ref></a>), unless and until the emergency use authorization request under such section 564 has been denied or the developer of such test does not submit a request under such section within a reasonable timeframe;</content>
</subparagraph>
<subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="C">“(C) </num><content>is developed in and authorized by a State that has notified the Secretary of Health and Human Services of its intention to review tests intended to diagnose COVID–19; or</content>
</subparagraph>
<subparagraph class="indent2 fontsize10" style="-uslm-lc:I650124"><num style="-uslm-lc:emspace2" value="D">“(D) </num><content>other test that the Secretary determines appropriate in guidance.”</content>
</subparagraph>
</paragraph>
</quotedContent>.</content>
</section></p>
        </div>  
    </body>